Equillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease
LA JOLLA, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast …